Eliza Atkinson

Eliza Atkinson
Imperial College London | Imperial · Department of Bioengineering

About

5
Publications
371
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
10
Citations

Publications

Publications (5)
Article
Full-text available
Background Low-cost sustainable feedstocks are essential for commercially viable biotechnologies. These feedstocks, often derived from plant or food waste, contain a multitude of different complex biomolecules which require multiple enzymes to hydrolyse and metabolise. Current standard biotechnology uses monocultures in which a single host expresse...
Article
In natural ecosystems, microorganisms live in communities where each member interacts with the others and with the environment to efficiently utilise available resources. Division of Labor (DOL) is an evolutionary strategy that evolved by microbial communities to accomplish complex tasks. Current bio-based technologies could also benefit from DOL i...
Chapter
Full-text available
Current design techniques for microbiome engineering focus on top‐down approaches. In contrast, synthetic biology tends to use bottom‐up engineering principles to design biological systems at various scales. This may enable complex microbial consortia to be created, where the underlying interactions can be better understood at a genetic and mechani...
Article
Full-text available
Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic resistance to these drugs and receive minimal cli...
Preprint
Full-text available
Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic resistance to these drugs and receive minimal cli...

Network

Cited By